<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242953</url>
  </required_header>
  <id_info>
    <org_study_id>SCO-120-19-18</org_study_id>
    <nct_id>NCT04242953</nct_id>
  </id_info>
  <brief_title>Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects</brief_title>
  <official_title>A Multipart Phase 1 Study to Determine Safety, Tolerability and Pharmacokinetics of SCO-120 in Healthy Male and Post-menopausal Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multipart Phase 1 Randomized, Double blind and Placebo controlled Study to&#xD;
      Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in healthy male and&#xD;
      postmenopausal female volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A- approximately 76 (Approximately 8 sequential cohorts of 8 subjects per cohort)&#xD;
&#xD;
      Part B- Up to approximately, 32 healthy males or post-menopausal female subjects will be&#xD;
      enrolled&#xD;
&#xD;
      Part C- Approximately 32 healthy male or postmenopausal female subjects (4 sequential cohorts&#xD;
      of 8 subjects) will be enrolled&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">March 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 16, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of subjects with treatment-related adverse events as assessed by CTCAE version 5.0</measure>
    <time_frame>Day 14</time_frame>
    <description>Part A: safety and tolerability assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Number of subjects with treatment-related adverse events as assessed by CTCAE version 5.0</measure>
    <time_frame>Day 35</time_frame>
    <description>Part C: safety and tolerability assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of subjects with treatment-related adverse events as assessed by CTCAE version 5.0</measure>
    <time_frame>Day 42</time_frame>
    <description>Part B: safety and tolerability assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>SCO-120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCO-120</intervention_name>
    <description>Part A: single oral administration&#xD;
Part B: single oral administration in Period 1 and Period 2 (crossover design)&#xD;
Part C: multiple oral administration (14 day dosing)</description>
    <arm_group_label>SCO-120</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>Part A: single oral administration&#xD;
Part C: multiple oral administration (14 day dosing)</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy postmenopausal female volunteers will be included in the study if they meet all of&#xD;
        the following criteria:&#xD;
&#xD;
        Part A-&#xD;
&#xD;
          1. Healthy postmenopausal female subjects, aged &gt; 18 years, Weight over 50 kg and with a&#xD;
             body mass index of 18.0 to 33.0 kg/m2 (inclusive) will be included in this part.&#xD;
&#xD;
          2. Did not donate 50-349 mL blood within 30 days or ≥350 mL blood within 3 months prior&#xD;
             to IMP administration and agrees not to make blood donations, including red blood&#xD;
             cells, plasma, platelets, or whole blood for the entire study duration.&#xD;
&#xD;
             Part B and C-&#xD;
&#xD;
          3. Healthy male and postmenopausal female subjects, aged ≥ 18 years, with a body mass&#xD;
             index of 18.0 to 33.0 kg/m2 (inclusive) will be included in this part.&#xD;
&#xD;
          4. Did not donate 50-499 mL blood within 30 days or ≥500 mL blood within 56 days prior to&#xD;
             IMP administration and agrees not to make blood donations, including red blood cells,&#xD;
             plasma, platelets, or whole blood for the entire study duration&#xD;
&#xD;
          5. Men who are able to father children must agree to use medically acceptable methods of&#xD;
             contraception and NOT donate sperm during the study and for 90 days after the end of&#xD;
             the study. Medically acceptable methods of contraception include using a condom with a&#xD;
             female partner of child-bearing potential who is using oral contraceptives, hormonal&#xD;
             patch, implant or injection, intrauterine device, or diaphragm with spermicide.&#xD;
             Abstinence as a method of contraception is acceptable if it is in line with the&#xD;
             preferred and usual lifestyle of the study participant.&#xD;
&#xD;
             All parts-&#xD;
&#xD;
          6. Willing and able to give written, signed and dated informed consent (or by subject's&#xD;
             legally acceptable representative/impartial witness when applicable) and is available&#xD;
             for the entire study&#xD;
&#xD;
          7. Willing and able to comply with the scheduled visits, treatment plan, laboratory&#xD;
             testing, study procedures, and restrictions (as per section 4.5), and be accessible&#xD;
             for follow-up visits&#xD;
&#xD;
          8. Assessed as healthy based on no clinically significant abnormality identified on&#xD;
             medical history, physical examination, vital signs, electrocardiogram (ECG), and&#xD;
             clinical laboratory screening tests&#xD;
&#xD;
          9. Females who are naturally postmenopausal for at least 12 consecutive months with a&#xD;
             follicle-stimulating hormone level of ≥ 40 mIU/mL at screening&#xD;
&#xD;
         10. Non-smokers or abstain from any tobacco usage, including smokeless tobacco, nicotine&#xD;
             patches, etc. for entire study duration including screening period; subjects must have&#xD;
             urine cotinine levels below those measured for smokers (&lt; 200 ng/mL) .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from the Study if they meet any of the following criteria: (All&#xD;
        Parts)&#xD;
&#xD;
          1. Any major surgery, as determined by the Investigator, within 4 weeks of IMP&#xD;
             administration;&#xD;
&#xD;
          2. Blood transfusion within 4 weeks prior to IMP administration;&#xD;
&#xD;
          3. Inability to swallow oral medication;&#xD;
&#xD;
          4. Inability to undergo venipuncture and/or tolerate venous access;&#xD;
&#xD;
          5. Female on Hormone Replacement Therapy, or having been on the same in the past 6&#xD;
             months;&#xD;
&#xD;
          6. Active liver disease or history of liver disease (such as hepatitis) in the past 6&#xD;
             months which can have impact on study endpoints and/ safety of subjects as per&#xD;
             investigator discretion;&#xD;
&#xD;
          7. Medical history of thromboembolic disorders or with risks (such as hematologic or&#xD;
             rheumatologic disorders); recent history of thrombophlebitis;&#xD;
&#xD;
          8. Subjects with complaints of hot flashes at screening;&#xD;
&#xD;
          9. History of abnormal vaginal bleeding within 3 months prior to screening and/ or&#xD;
             uterine malignancy&#xD;
&#xD;
         10. Positive exclusion tests: human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen, or hepatitis C virus;&#xD;
&#xD;
         11. History of any relevant allergy/hypersensitivity (including known immediate or delayed&#xD;
             hypersensitivity reaction or idiosyncrasy to drugs chemically related to the IMP or&#xD;
             its excipients);&#xD;
&#xD;
         12. Received another investigational agent within 30 days (or for investigational agents&#xD;
             with long half life a washout of 5 half-lives will be required) prior to IMP&#xD;
             administration or intake of an investigational drug during the course of this study;&#xD;
&#xD;
         13. Intake of any prescribed medication/drugs within at least 14 days and/or&#xD;
             over-the-counter drugs within at least 7 days (or less than 5 half-lives of the&#xD;
             respective drug) prior to administration of the IMP;&#xD;
&#xD;
         14. Known and/ or suspected history of significant drug abuse as judged by the&#xD;
             Investigator;&#xD;
&#xD;
         15. Positive screen for drugs of abuse at Screening visit or positive screen for alcohol&#xD;
             or drugs of abuse on admission to the study centre prior to the first IMP&#xD;
             administration;&#xD;
&#xD;
         16. History of alcohol abuse or excessive intake of alcohol, defined as regular weekly&#xD;
             intake of more than 15 units of alcohol (Note: 1 unit equals 25 mL spirits, 125 mL&#xD;
             wine, or 250 mL beer or lager) in the 12 months prior to study entry;&#xD;
&#xD;
         17. Current or recent disease of the gastrointestinal tract that may impact drug&#xD;
             absorption and may affect the PK of the IMP, or any gastrointestinal tract surgery&#xD;
             history that may impact drug absorption;&#xD;
&#xD;
         18. Continued use of caffeine or grapefruit juice or xanthine-containing drinks or food,&#xD;
             e.g., coffee, tea, chocolate, red bull, or cola for 48 hours prior to dosing and till&#xD;
             the last PK sample collection;&#xD;
&#xD;
         19. Any concomitant clinically significant disorder, like infection, diabetes etc. that&#xD;
             would pose a risk to subject safety or interfere with the study evaluation,&#xD;
             procedures, or completion which can have impact on study endpoints and/ safety of&#xD;
             subjects as per PI discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Part A- Healthy postmenopausal female volunteers&#xD;
Part B &amp; Part C- Healthy Male or postmenopausal female volunteers</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head, Clinical Developement</last_name>
    <phone>+1 (609) 720-5333</phone>
    <email>clinical.trials@sparcmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AXIS Clinicals</name>
      <address>
        <city>Dilworth</city>
        <state>Minnesota</state>
        <zip>56529-1342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Swarna Yadlapalli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioPharma Services USA Inc.</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Artan Markollari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioPharma Services Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON M9L 3A2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Esmat Dessouki</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

